Treatment Combinations for Alzheimer’s Disease: Current And Future Pharmacotherapy Options

Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease

(2018) Alireza Atri et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

(2018) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination products: modernizing the regulatory paradigm

(2017) Nina L. Hunter et al.   NATURE REVIEWS DRUG DISCOVERY

I-SPY 2 Breast Cancer Trial as a Model for Innovation in Alzheimer Disease Therapies

(2017) Mindi F. Messmer et al.   JAMA Neurology

EXPLORATORY ANALYSES OF COGNITIVE EFFECTS OF CRENEZUMAB IN A MILD ALZHEIMER'S DISEASE SUBPOPULATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY (ABBY)

(2016) Howard Mackey et al.   Alzheimers & Dementia

Challenges, solutions, and recommendations for Alzheimer's disease combination therapy

(2016) James A. Hendrix et al.   Alzheimers & Dementia

2016 Alzheimer's disease facts and figures

(2016)   Alzheimers & Dementia

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

(2016) Serge Gauthier et al.   LANCET

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Tratamiento de la enfermedad de Alzheimer mediante terapia combinada de aféresis terapéutica y hemoféresis con albúmina e inmunoglobulina intravenosa: fundamentos y aproximación terapéutica al estudio AMBAR (Alzheimer Management By Albumin Replacement)

(2016) M. Boada et al.   NEUROLOGIA

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS  -amyloid in animal models and in Alzheimers disease patients

(2016) M. E. Kennedy et al.   Science Translational Medicine

The Role of Mast Cells in Alzheimer’s Disease

(2016) Yasdani Shaik-Dasthagirisaheb et al.   Advances in Clinical and Experimental Medicine

Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies

(2014) John M. Ringman et al.   Current Neurology and Neuroscience Reports

A Food and Drug Administration-approved Asthma Therapeutic Agent Impacts Amyloid β in the Brain in a Transgenic Model of Alzheimer Disease

(2014) Yukiko Hori et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

(2014) David Wilkinson et al.   LANCET NEUROLOGY

Targeting the β secretase BACE1 for Alzheimer's disease therapy

(2014) Riqiang Yan et al.   LANCET NEUROLOGY

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

(2014) Jeffrey L Cummings et al.   Alzheimers Research & Therapy

Tau-aggregation inhibitor therapy for Alzheimer's disease

(2013) Claude M. Wischik et al.   BIOCHEMICAL PHARMACOLOGY

Treatment Strategies Targeting Amyloid  -Protein

(2013) D. Schenk et al.   Cold Spring Harbor Perspectives in Medicine

AlzPathway: a comprehensive map of signaling pathways of Alzheimer’s disease

(2012) Satoshi Mizuno et al.   BMC Systems Biology

Is RAGE still a therapeutic target for Alzheimer’s disease?

(2012) Richard J Deane   Future Medicinal Chemistry

Efficacy of Memantine for Agitation in Alzheimer’s Dementia: A Randomised Double-Blind Placebo Controlled Trial

(2012) Chris Fox et al.   PLoS One

Efficacy and Tolerability of Antidepressants in the Treatment of Behavioral and Psychological Symptoms of Dementia, A Literature Review of Evidence

(2011) Genevieve Henry et al.   American Journal of Alzheimers Disease and Other Dementias

Evidence for Ordering of Alzheimer Disease Biomarkers

(2011) Clifford R. Jack   ARCHIVES OF NEUROLOGY

Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights into the Mechanism of Amyloid-  Immunotherapy

(2011) A. Wang et al.   JOURNAL OF NEUROSCIENCE

Epidemiology of Alzheimer disease

(2011) Christiane Reitz et al.   Nature Reviews Neurology

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

(2011) François Piette et al.   Alzheimers Research & Therapy

Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces Pseudobulbar Affect

(2010) Erik P. Pioro et al.   ANNALS OF NEUROLOGY

Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications

(2008) Elliott J Mufson et al.   Expert Review of Neurotherapeutics

The antioxidant properties of serum albumin

(2008) Marjolaine Roche et al.   FEBS LETTERS

5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease

(2008) Neil Upton et al.   Neurotherapeutics